These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 32784899)

  • 1. SARS-CoV-2 Entry Inhibitors: Small Molecules and Peptides Targeting Virus or Host Cells.
    Cannalire R; Stefanelli I; Cerchia C; Beccari AR; Pelliccia S; Summa V
    Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32784899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein.
    Johnson MC; Lyddon TD; Suarez R; Salcedo B; LePique M; Graham M; Ricana C; Robinson C; Ritter DG
    J Virol; 2020 Oct; 94(21):. PubMed ID: 32788194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting Host Cell Proteases to Prevent SARS-CoV-2 Invasion.
    Kaur U; Chakrabarti SS; Ojha B; Pathak BK; Singh A; Saso L; Chakrabarti S
    Curr Drug Targets; 2021; 22(2):192-201. PubMed ID: 32972339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity.
    Zhu Y; Yu D; Yan H; Chong H; He Y
    J Virol; 2020 Jul; 94(14):. PubMed ID: 32376627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Furin Inhibitors Block SARS-CoV-2 Spike Protein Cleavage to Suppress Virus Production and Cytopathic Effects.
    Cheng YW; Chao TL; Li CL; Chiu MF; Kao HC; Wang SH; Pang YH; Lin CH; Tsai YM; Lee WH; Tao MH; Ho TC; Wu PY; Jang LT; Chen PJ; Chang SY; Yeh SH
    Cell Rep; 2020 Oct; 33(2):108254. PubMed ID: 33007239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LY6E Restricts Entry of Human Coronaviruses, Including Currently Pandemic SARS-CoV-2.
    Zhao X; Zheng S; Chen D; Zheng M; Li X; Li G; Lin H; Chang J; Zeng H; Guo JT
    J Virol; 2020 Aug; 94(18):. PubMed ID: 32641482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SARS-CoV-2 Evolutionary Adaptation toward Host Entry and Recognition of Receptor O-Acetyl Sialylation in Virus-Host Interaction.
    Kim CH
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32604730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a Potential Peptide Inhibitor of SARS-CoV-2 Targeting its Entry into the Host Cells.
    Baig MS; Alagumuthu M; Rajpoot S; Saqib U
    Drugs R D; 2020 Sep; 20(3):161-169. PubMed ID: 32592145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Existence of SARS-CoV-2 Entry Molecules in the Oral Cavity.
    Sakaguchi W; Kubota N; Shimizu T; Saruta J; Fuchida S; Kawata A; Yamamoto Y; Sugimoto M; Yakeishi M; Tsukinoki K
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32825469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the intestinal TMPRSS2 protease to prevent SARS-CoV-2 entry into enterocytes-prospects and challenges.
    Mahmoud IS; Jarrar YB
    Mol Biol Rep; 2021 May; 48(5):4667-4675. PubMed ID: 34023987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simultaneous Inhibition of SARS-CoV-2 Entry Pathways by Cyclosporine.
    Prasad K; Ahamad S; Kanipakam H; Gupta D; Kumar V
    ACS Chem Neurosci; 2021 Mar; 12(5):930-944. PubMed ID: 33606519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COVID-19 pandemic: Insights into structure, function, and hACE2 receptor recognition by SARS-CoV-2.
    Mittal A; Manjunath K; Ranjan RK; Kaushik S; Kumar S; Verma V
    PLoS Pathog; 2020 Aug; 16(8):e1008762. PubMed ID: 32822426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coevolution, Dynamics and Allostery Conspire in Shaping Cooperative Binding and Signal Transmission of the SARS-CoV-2 Spike Protein with Human Angiotensin-Converting Enzyme 2.
    Verkhivker G
    Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33158276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19.
    Huang Y; Yang C; Xu XF; Xu W; Liu SW
    Acta Pharmacol Sin; 2020 Sep; 41(9):1141-1149. PubMed ID: 32747721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted therapy strategies against SARS-CoV-2 cell entry mechanisms: A systematic review of in vitro and in vivo studies.
    Seyedpour S; Khodaei B; Loghman AH; Seyedpour N; Kisomi MF; Balibegloo M; Nezamabadi SS; Gholami B; Saghazadeh A; Rezaei N
    J Cell Physiol; 2021 Apr; 236(4):2364-2392. PubMed ID: 32901936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Highly conserved binding region of ACE2 as a receptor for SARS-CoV-2 between humans and mammals.
    Hayashi T; Abiko K; Mandai M; Yaegashi N; Konishi I
    Vet Q; 2020 Dec; 40(1):243-249. PubMed ID: 32921279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In Silico Identification of Potential Natural Product Inhibitors of Human Proteases Key to SARS-CoV-2 Infection.
    Vivek-Ananth RP; Rana A; Rajan N; Biswal HS; Samal A
    Molecules; 2020 Aug; 25(17):. PubMed ID: 32842606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heparin-binding Peptides as Novel Therapies to Stop SARS-CoV-2 Cellular Entry and Infection.
    Tavassoly O; Safavi F; Tavassoly I
    Mol Pharmacol; 2020 Nov; 98(5):612-619. PubMed ID: 32913137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting Proteases for Treating COVID-19.
    Luan B; Huynh T; Cheng X; Lan G; Wang HR
    J Proteome Res; 2020 Nov; 19(11):4316-4326. PubMed ID: 33090793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural Basis for the Understanding of Entry Inhibitors against SARS Viruses.
    Kushwaha PK; Kumari N; Nayak S; Kishor K; Sharon A
    Curr Med Chem; 2022; 29(4):666-681. PubMed ID: 33992054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.